a From Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; University of Rochester Medical Center, University of Rochester, Rochester, New York; and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
The NPM-ALK fusion protein is found in ALK+ anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK+ anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK+ anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.
Correspondence: James M. Cleary, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215. E-mail: email@example.com